Evidence map›Paper›PMID 36232692›Full record

ReviewInternational journal of molecular sciences2022

Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021.

Chunyan Zhang, Caifang Sun, Yabin Zhao, Qiwen Wang, Jianlin Guo, Bingyu Ye, Guoying Yu

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chunyan ZhangState Key Laboratory Cell Differentiation and Regulation, Henan Normal University, Xinxiang 453007, China.
Caifang SunState Key Laboratory Cell Differentiation and Regulation, Henan Normal University, Xinxiang 453007, China.
Yabin ZhaoState Key Laboratory Cell Differentiation and Regulation, Henan Normal University, Xinxiang 453007, China.
Qiwen WangState Key Laboratory Cell Differentiation and Regulation, Henan Normal University, Xinxiang 453007, China.
Jianlin GuoState Key Laboratory Cell Differentiation and Regulation, Henan Normal University, Xinxiang 453007, China.
Bingyu YeState Key Laboratory Cell Differentiation and Regulation, Henan Normal University, Xinxiang 453007, China.ORCID 0000-0001-6772-5063
Guoying YuState Key Laboratory Cell Differentiation and Regulation, Henan Normal University, Xinxiang 453007, China.
Henan Normal University · CN

Funding

Our research has been funded the Natural Science Foundation of China (32000125), the National Fostering Science Fund Project of Henan Normal University (20A180014), Doctoral Research Foundation of Henan Normal University(5101049170192), Scientific and tec Our research has been funded the Natural Science Foundation of China (32000125), the National Fostering Science Fund Project of Henan Normal University (20A180014), Doctoral Research Foundation of Henan Normal University(5101049170192), Scientific and tec
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs (ncRNAs) about 22 nucleotides in size, which play an important role in gene regulation and are involved in almost all major cellular physiological processes. In recent years, the abnormal expression of miRNAs has been shown to be associated with human diseases including cancer. In the past ten years, the link between miRNAs and various cancers has been extensively studied, and the abnormal expression of miRNAs has been reported in various malignant tumors, such as lung cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer, and prostate cancer. Due to the high malignancy grade of these cancers, it is more necessary to develop the related diagnostic and prognostic methods. According to the study of miRNAs, many potential cancer biomarkers have been proposed for the diagnosis and prognosis of diseases, especially cancer, thus providing a new theoretical basis and perspective for cancer screening. The use of miRNAs as biomarkers for diagnosis or prognosis of cancer has the advantages of being less invasive to patients, with better accuracy and lower price. In view of the important clinical significance of miRNAs in human cancer research, this article reviewed the research status of miRNAs in the above-mentioned cancers in 2021, especially in terms of diagnosis and prognosis, and provided some new perspectives and theoretical basis for the diagnosis and treatment of cancers.

Indexed as

MicroRNAsNeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansIncidenceLiver NeoplasmsNucleotidesPrognosisBiomarkers, TumorMicroRNAsNucleotidesbiomarkercancerdiagnosismiRNAsprognosis

Identifiers

PMID36232692
PMCPMC9570028
OpenAlexW4297540219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.